Compare Heron Therapeutics Inc (HRTX) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Standard Lithium Ltd — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while Standard Lithium Ltd trades at $1.61 (market cap $398.07M). The key difference: Standard Lithium Ltd is far larger — about 5.9× Heron Therapeutics Inc's market cap, and Heron Therapeutics Inc is more actively traded (1,891,941 versus 1,564,155). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Standard Lithium Ltd for 23 Days on average.
| HRTX | SLI | |
|---|---|---|
Market Cap | $68.01M | $398.07M |
Volume | 1,891,941 | 1,564,155 |
Sector | Health | Basic Materials |
52-Week High | $1.49 | $5.65 |
52-Week Low | $0.27 | $1.61 |
Typical Hold Time | 35 Days | 23 Days |
Enterprise Value | $174.75M | $260.98M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Standard Lithium (SLI) trades at $1.65, down 4.62% today, with a bearish technical signal despite bullish oscillators. The company shows negative profitability with ROE of -15.55% and ROA of -14.17%, though recent quarterly EPS beat expectations. Positive developments include progress toward a 2026 final investment decision for the Arkansas lithium project and expanded offtake agreements. Cash flow remains supported by financing activities despite negative operational cash flow.
The investment case hinges on successful project execution and lithium market dynamics. Analysts are unanimously bullish with a $3.83 price target, representing significant upside. Key risks include execution delays, negative cash flow, and commodity price volatility. The stock offers high-risk, high-reward exposure to North American lithium production growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
